Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (33)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kawamori, T.
Right arrow Articles by Wakabayashi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawamori, T.
Right arrow Articles by Wakabayashi, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 22, No. 12, 2001-2004, December 2001
© 2001 Oxford University Press

MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION

Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP1 antagonist, on breast cancer development

Toshihiko Kawamori1,3, Naoaki Uchiya1, Seiichi Nakatsugi1, Kouji Watanabe1, Shuichi Ohuchida2, Hiroshi Yamamoto2, Takayuki Maruyama2, Kigen Kondo2, Takashi Sugimura1 and Keiji Wakabayashi1

1 Cancer Prevention Division, National Cancer Center Research Institute, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045 and
2 Minase Research Institute, Ono Pharmaceutical Co. Ltd., 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan

Levels of prostaglandin E2 (PGE2) in human and rodent breast cancers are higher than surrounding normal tissues. PGE2 exhibits biological activity through binding to membrane receptors, EP1–4. The present study was designed to investigate the effects of ONO-8711, a newly synthesized selective PGE receptor EP1 antagonist, on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced breast cancer development. Starting at 7 weeks of age, female Sprague–Dawley (SD) rats were given PhIP (85 mg/kg body weight) by gavage four times weekly for two weeks. Dietary administration of ONO-8711 at 400 or 800 p.p.m. delayed occurrence of breast tumors for 2 or 4 weeks, respectively. At 20 weeks after the last dosing of PhIP, all animals were killed and complete autopsy was made. All breast tumors were diagnosed as invasive ductal adenocarcinomas histopathologically. Administration of ONO-8711 at 800 p.p.m. significantly decreased PhIP-induced breast cancer incidence, multiplicity and volume compared with those of rats fed the control diet (56% versus 79%, P < 0.05, 1.2 versus 2.5, P < 0.05, 0.7 versus 1.4 cm3, P < 0.01, respectively). Apoptosis was significantly increased in breast cancer cells by feeding of ONO-8711 at 800 p.p.m. of 158% (P < 0.05). EP1 receptor was detected by reverse transcription-polymerase chain reaction (RT-PCR) in breast cancers, not in normal tissues. These results suggest that EP1 receptor is associated with breast cancer development and selective PGE receptor EP1 antagonists may possess chemopreventive effects through the induction of apoptosis without any side effects.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
P. Sinha, V. K. Clements, A. M. Fulton, and S. Ostrand-Rosenberg
Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells
Cancer Res., May 1, 2007; 67(9): 4507 - 4513.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. Makita, M. Mutoh, T. Maruyama, K. Yonemoto, A. Kobayashi, H. Fujitsuka, M. Toida, T. Shibata, S. Miyamoto, Y. Yasui, et al.
A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis
Carcinogenesis, March 1, 2007; 28(3): 677 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. M. Fulton, X. Ma, and N. Kundu
Targeting Prostaglandin E EP Receptors to Inhibit Metastasis.
Cancer Res., October 15, 2006; 66(20): 9794 - 9797.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Ma, N. Kundu, S. Rifat, T. Walser, and A. M. Fulton
Prostaglandin E Receptor EP4 Antagonism Inhibits Breast Cancer Metastasis.
Cancer Res., March 15, 2006; 66(6): 2923 - 2927.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
D Wang and R N DuBois
PROSTAGLANDINS AND CANCER
Gut, January 1, 2006; 55(1): 115 - 122.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. Mendez and M. C. LaPointe
PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation
Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2111 - H2117.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Golijanin, J.-Y. Tan, A. Kazior, E. G. Cohen, P. Russo, G. Dalbagni, K. J. Auborn, K. Subbaramaiah, and A. J. Dannenberg
Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Are Overexpressed in Squamous Cell Carcinoma of the Penis
Clin. Cancer Res., February 1, 2004; 10(3): 1024 - 1031.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. G. Cohen, T. Almahmeed, B. Du, D. Golijanin, J. O. Boyle, R. A. Soslow, K. Subbaramaiah, and A. J. Dannenberg
Microsomal Prostaglandin E Synthase-1 Is Overexpressed in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., August 1, 2003; 9(9): 3425 - 3430.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. R. Howe, K. Subbaramaiah, J. Patel, J. L. Masferrer, A. Deora, C. Hudis, H. T. Thaler, W. J. Muller, B. Du, A. M. C. Brown, et al.
Celecoxib, a Selective Cyclooxygenase 2 Inhibitor, Protects against Human Epidermal Growth Factor Receptor 2 (HER-2)/neu-induced Breast Cancer
Cancer Res., October 1, 2002; 62(19): 5405 - 5407.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.